Literature DB >> 33184509

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells.

Isabel Schulien1, Janine Kemming1,2, Valerie Oberhardt1,2, Katharina Wild1,3, Lea M Seidel1,2,4,5, Saskia Killmer1, Franziska Daul1,2, Marilyn Salvat Lago1, Annegrit Decker1, Hendrik Luxenburger1,6, Benedikt Binder1,6, Dominik Bettinger1,7, Oezlem Sogukpinar1, Siegbert Rieg1, Marcus Panning8, Daniela Huzly8, Martin Schwemmle8, Georg Kochs8, Cornelius F Waller9, Alexandra Nieters10, Daniel Duerschmied11, Florian Emmerich12, Henrik E Mei13, Axel Ronald Schulz13, Sian Llewellyn-Lacey14, David A Price14,15, Tobias Boettler1,7, Bertram Bengsch1,5, Robert Thimme16, Maike Hofmann17, Christoph Neumann-Haefelin18.   

Abstract

Emerging data indicate that SARS-CoV-2-specific CD8+ T cells targeting different viral proteins are detectable in up to 70% of convalescent individuals1-5. However, very little information is currently available about the abundance, phenotype, functional capacity and fate of pre-existing and induced SARS-CoV-2-specific CD8+ T cell responses during the natural course of SARS-CoV-2 infection. Here, we define a set of optimal and dominant SARS-CoV-2-specific CD8+ T cell epitopes. We also perform a high-resolution ex vivo analysis of pre-existing and induced SARS-CoV-2-specific CD8+ T cells, applying peptide-loaded major histocompatibility complex class I (pMHCI) tetramer technology. We observe rapid induction, prolonged contraction and emergence of heterogeneous and functionally competent cross-reactive and induced memory CD8+ T cell responses in cross-sectionally analyzed individuals with mild disease following SARS-CoV-2 infection and three individuals longitudinally assessed for their T cells pre- and post-SARS-CoV-2 infection. SARS-CoV-2-specific memory CD8+ T cells exhibited functional characteristics comparable to influenza-specific CD8+ T cells and were detectable in SARS-CoV-2 convalescent individuals who were seronegative for anti-SARS-CoV-2 antibodies targeting spike (S) and nucleoprotein (N). These results define cross-reactive and induced SARS-CoV-2-specific CD8+ T cell responses as potentially important determinants of immune protection in mild SARS-CoV-2 infection.

Entities:  

Year:  2020        PMID: 33184509     DOI: 10.1038/s41591-020-01143-2

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  101 in total

1.  Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells during Convalescence.

Authors:  Tongcui Ma; Heeju Ryu; Matthew McGregor; Benjamin Babcock; Jason Neidleman; Guorui Xie; Ashley F George; Julie Frouard; Victoria Murray; Gurjot Gill; Eliver Ghosn; Evan W Newell; Sulggi A Lee; Nadia R Roan
Journal:  J Immunol       Date:  2021-08-13       Impact factor: 5.422

2.  SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.

Authors:  Hassen Kared; Andrew D Redd; Evan M Bloch; Tania S Bonny; Hermi Sumatoh; Faris Kairi; Daniel Carbajo; Brian Abel; Evan W Newell; Maria P Bettinotti; Sarah E Benner; Eshan U Patel; Kirsten Littlefield; Oliver Laeyendecker; Shmuel Shoham; David Sullivan; Arturo Casadevall; Andrew Pekosz; Alessandra Nardin; Michael Fehlings; Aaron Ar Tobian; Thomas C Quinn
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

3.  Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.

Authors:  Pui Wang; Siu-Ying Lau; Shaofeng Deng; Pin Chen; Bobo Wing-Yee Mok; Anna Jinxia Zhang; Andrew Chak-Yiu Lee; Kwok-Hung Chan; Rachel Chun-Yee Tam; Haoran Xu; Runhong Zhou; Wenjun Song; Li Liu; Kelvin Kai-Wang To; Jasper Fuk-Woo Chan; Zhiwei Chen; Kwok-Yung Yuen; Honglin Chen
Journal:  Nat Commun       Date:  2021-05-13       Impact factor: 14.919

4.  SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients.

Authors:  Ditte Stampe Hersby; Tripti Tamhane; Sunil Kumar Saini; Helle Rus Povlsen; Susana Patricia Amaya Hernandez; Morten Nielsen; Anne Ortved Gang; Sine Reker Hadrup
Journal:  Sci Immunol       Date:  2021-04-14

5.  Age groups that sustain resurging COVID-19 epidemics in the United States.

Authors:  Mélodie Monod; Alexandra Blenkinsop; Xiaoyue Xi; Daniel Hebert; Sivan Bershan; Simon Tietze; Oliver Ratmann; Marc Baguelin; Valerie C Bradley; Yu Chen; Helen Coupland; Sarah Filippi; Jonathan Ish-Horowicz; Martin McManus; Thomas Mellan; Axel Gandy; Michael Hutchinson; H Juliette T Unwin; Sabine L van Elsland; Michaela A C Vollmer; Sebastian Weber; Harrison Zhu; Anne Bezancon; Neil M Ferguson; Swapnil Mishra; Seth Flaxman; Samir Bhatt
Journal:  Science       Date:  2021-02-02       Impact factor: 47.728

6.  SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses.

Authors:  Benedikt Agerer; Maximilian Koblischke; Venugopal Gudipati; Luis Fernando Montaño-Gutierrez; Mark Smyth; Alexandra Popa; Jakob-Wendelin Genger; Lukas Endler; David M Florian; Vanessa Mühlgrabner; Marianne Graninger; Stephan W Aberle; Anna-Maria Husa; Lisa Ellen Shaw; Alexander Lercher; Pia Gattinger; Ricard Torralba-Gombau; Doris Trapin; Thomas Penz; Daniele Barreca; Ingrid Fae; Sabine Wenda; Marianna Traugott; Gernot Walder; Winfried F Pickl; Volker Thiel; Franz Allerberger; Hannes Stockinger; Elisabeth Puchhammer-Stöckl; Wolfgang Weninger; Gottfried Fischer; Wolfgang Hoepler; Erich Pawelka; Alexander Zoufaly; Rudolf Valenta; Christoph Bock; Wolfgang Paster; René Geyeregger; Matthias Farlik; Florian Halbritter; Johannes B Huppa; Judith H Aberle; Andreas Bergthaler
Journal:  Sci Immunol       Date:  2021-03-04

7.  Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform.

Authors:  Ahmed Abdul Quadeer; Syed Faraz Ahmed; Matthew R McKay
Journal:  Cell Rep Med       Date:  2021-05-21

8.  Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses.

Authors:  Anusha Nathan; Elizabeth J Rossin; Clarety Kaseke; Ryan J Park; Ashok Khatri; Dylan Koundakjian; Jonathan M Urbach; Nishant K Singh; Arman Bashirova; Rhoda Tano-Menka; Fernando Senjobe; Michael T Waring; Alicja Piechocka-Trocha; Wilfredo F Garcia-Beltran; A John Iafrate; Vivek Naranbhai; Mary Carrington; Bruce D Walker; Gaurav D Gaiha
Journal:  Cell       Date:  2021-06-30       Impact factor: 66.850

Review 9.  Insights into the virologic and immunologic features of SARS-COV-2.

Authors:  Ceylan Polat; Koray Ergunay
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

10.  Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2.

Authors:  Ye Feng; Haiping Jiang; Min Qiu; Liang Liu; Shengmei Zou; Yun Li; Qianpeng Guo; Ning Han; Yingqiang Sun; Kui Wang; Lantian Lu; Xinlei Zhuang; Shanshan Zhang; Shuqing Chen; Fan Mo
Journal:  Pathogens       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.